ProCE Banner Activity

CHRYSALIS-2: Update of Amivantamab + Lazertinib in EGFR-Mutant NSCLC After Progression on Osimertinib and Chemotherapy

Slideset Download
Updated results from the phase I CHRYSALIS-2 trial showed durable antitumor activity with amivantamab + lazertinib in patients with EGFR-mutated NSCLC after progression on both osimertinib and chemotherapy.

Released: June 14, 2022

Expiration: June 13, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab